The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
Lutio has the potential to offer significant cost savings when available to UK patients.
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The clinical research organisation located in Hyderabad is a USFDA inspected facility
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
Alkem Medtech to acquire 100% stake of Bombay Ortho
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Subscribe To Our Newsletter & Stay Updated
